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Abstract: In HBV/HIV-coinfected patients, the risk of end-stage liver disease and death is increased. This open-label, 
prospective, pilot study evaluated abacavir/lamivudine/zidovudine twice daily plus tenofovir once daily in HBV/HIV-
coinfected antiretroviral-naïve subjects. Nine adults (8 males) enrolled, with baseline mean HIV-1 RNA = 4.5 log10 
copies/mL, HBV DNA = 9.0 log10 copies/mL, and median CD4 count =158 cells/mm
3. No subject had baseline ALT >5x 
ULN. 
Six subjects completed the study: 1 withdrew due to non-treatment-related toxoplasmosis and 2 were lost-to-follow-up. At 
week 48, 100% (6/6) of remaining subjects had 2 log10 decrease in HBV DNA, and 100% (6/6) and 83% (5/6) had HIV-
1 RNA <400 and <50 copies/mL, respectively. Median change from baseline in CD4 count was 157 cells/mm
3. One 
subject experienced treatment-related grade 3 leukopenia. These results demonstrate that abacavir/lamivudine/zidovudine 
and tenofovir were well tolerated with sustained HIV-1 and HBV antiviral activity through 48 weeks in HBV/HIV-
coinfected, antiretroviral-naïve subjects.  
Keywords: HIV, coinfection, hepatitis B, abacavir, lamivudine,  zidovudine, tenofovir. 
DEAR EDITOR: 
  AIDS-related morbidity and mortality have declined as a 
result of highly active antiretroviral therapy (HAART); 
however, liver disease caused by chronic hepatitis B virus 
(HBV) infection remains an important cause of morbidity 
and mortality among HIV-infected patients
  [1,2]. In 
HBV/HIV-coinfected patients, the risk of end-stage liver 
disease and death is increased, and liver histological damage 
may progress more rapidly leading to cirrhosis in a shortened 
timeframe [3]. 
  Current treatment guidelines for HBV/HIV coinfected 
patients recommend lamivudine (3TC) or emtricitabine in 
combination with tenofovir (TDF) to potentially reduce the 
risk of HBV resistance associated with 3TC monotherapy 
[4]. Abacavir/3TC/zidovudine (ABC/3TC/ZDV; Trizivir, 
GlaxoSmithKline, Research Triangle Park, North Carolina) 
is a fixed-dose combination product containing three 
nucleoside reverse transcriptase inhibitors (NRTIs): 300 mg 
ABC, 150 mg 3TC, and 300 mg ZDV, for the treatment of 
HIV infection. ABC/3TC/ZDV is administered as 1 tablet 
taken twice daily and has been shown to facilitate treatment 
adherence [5,6]. The clinical safety and efficacy of 
ABC/3TC/ZDV has been demonstrated in several clinical 
trials. TDF is a nucleotide reverse transcriptase inhibitor 
approved for the treatment of HIV infection in combination  
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with other agents at a recommended dose of 300 mg (1 
tablet) once daily. TDF is approved for hepatitis B therapy, 
and data from clinical trials have confirmed the activity of 
TDF in both 3TC-naïve and 3TC-resistant HBV patients 
[7,8]. 
  In this open-label, prospective, pilot study, we evaluated 
the long-term efficacy and safety of ABC/3TC/ZDV twice 
daily coadministered with TDF once daily in HBV/HIV-
coinfected antiretroviral-naïve subjects. At the time this 
study was designed, ABC/3TC/ZDV was recommended by 
the DHHS Panel on Clinical Practices for Treatment of HIV 
Infection  as an alternative regimen in treatment-naive 
patients [9], and data on the use of TDF in this population 
had only recently become available [10]. In that context, this 
regimen provided a straightforward dosing regimen 
uncomplicated by food or fluid restrictions and a low daily 
pill burden, and it is also nucleoside reverse transcriptase 
inhibitors (NNRTI)- and protease inhibitor (PI)- sparing to 
preserve future HIV treatment options. 
  Nine subjects with documented HIV-1 and HBV 
infection were enrolled at 5 centers in the United States 
between October 2003 and March 2005. Inclusion criteria 
included subjects who were ART-naïve, older than 18 years 
of age, had a CD4 count 100 cells/mm
3, a plasma HIV-1 
RNA count 1000 copies/mL, a HBV DNA viral load 
>1,000,000 copies/mL, and were HBsAg positive, HBsAb 
negative, HBeAg positive, and HBeAb negative. Subjects 
were excluded if they had an AIDS-defining illness within 
30 days of screening. All subjects provided written informed 
consent to participate, and the protocol for the study was 168    The Open AIDS Journal, 2010, Volume 4  Rodriguez et al. 
approved by the institutional review boards for each study 
site. 
  At each study visit, patients were monitored for adverse 
events and laboratory abnormalities using routine 
hematology and clinical chemistry panels that were 
processed at a central laboratory facility. Medication 
adherence was documented using pill counts, and 
measurements of HBV DNA, HIV-1 RNA, and CD4 cell 
counts were made throughout the study. HIV-1 RNA levels 
were determined using the Roche Amplicor HIV-1 Monitor 
COBAS UltraSensitive test (version 1.5; range of detection, 
51-75,000 copies/mL) and the standard test (range of 
detection, 400-750,000 copies/mL). HBV DNA levels were 
measured using an independently validated real-time PCR 
assay performed at a central laboratory. Genotypic analyses 
of baseline HIV and HBV isolates were determined using the 
TRUGENE HIV-1 Genotyping Kit (Bayer HealthCare LLC, 
Tarrytown, NY) and an independently validated polymerase 
chain reaction/sequencing assay (Quest Diagnostics Nichols 
Institute, San Juan Capistrano, CA), respectively. Phenotypic 
analysis of baseline HIV isolates was determined using the 
PhenoSense GT assay (Monogram Biosciences, South San 
Francisco, CA). 
  HIV-1 virologic failure was defined as HIV-1 RNA 400 
copies/mL at week 24 or later that was confirmed by a 
second measurement of HIV-1 RNA 400 copies/mL less 
than 4 weeks after the first measurement. Confirmed HBV 
virologic failure was defined as a <2 log10 copies/mL decline 
in HBV at week 24. The primary efficacy endpoint was 
proportion of subjects with a 2 log10 copies/mL decrease in 
HBV DNA viral load at week 48. The analysis population 
included all enrolled subjects that consumed at least one 
dose of study drug. 
  Of the 9 subjects enrolled, 8 were male and 1 was female. 
Three subjects were white, 2 were black, and 4 were 
American Hispanic. The mean age ±standard deviation (SD) 
was 39.4 ±11.06 years. At baseline, the mean ±SD HBV 
DNA viral load was 9.0 ±0.6 log10 copies/mL and the mean 
±SD HIV-1 RNA viral load was 4.5 ±0.77 log10 copies/mL. 
The median (range) CD4 cell count was 158 cells/mm
3 (97–
596 cells/mm
3). The median (range) alanine aminotrans-
ferase (ALT) level was 55 IU/L (30–144 IU/L). No subject 
had abnormal (>5 times the upper limit [48 IU/L] of the 
normal range) ALT levels at baseline. No HIV-1 NRTI 
mutations were detected in any of the 9 subjects at baseline. 
Likewise, no mutations were observed at YMDD/M552 or 
FLLAQ/L528 in the HBV polymerase from any of the 9 
subjects at baseline. 
  Six subjects completed the study and 3 subjects 
discontinued the study before week 48: 1 withdrew because 
of a medical condition unrelated to study drug, and 2 were 
lost to follow-up. None of the subjects experienced protocol-
defined HBV virologic failure. One subject (HIV-1 RNA 
740 copies/mL at week 24) was an unconfirmed HIV-1 
virologic failure (patient did not return after week 24 visit); 
no other subject experienced protocol-defined HIV-1 
virologic failure. 
  The time course of the change from baseline in HIV-1 
RNA levels for all 9 subjects is shown in Fig. (1A). At week 
48, 100% (6/6) and 83% (5/6) of subjects had plasma HIV-1 
viral load <400 copies/mL and <50 copies/mL, respectively. 
The mean change from baseline in HIV-1 RNA levels at 
week 48 was -2.9 log10 copies/mL. The median (range) CD4 
cell count at week 48 was 356 cells/mm
3 (179–695 
cells/mm
3) and the median (range) change from baseline in 
CD4 cell counts was 157 cells/mm
3 (62–253 cells/mm
3). 
 Fig.  (1B) shows the time course of the change from 
baseline in HBV DNA levels for all 9 subjects. At week 48, 
100% (6/6) of subjects had a 2 log10 copies/mL decrease in 
HBV DNA viral load, and the mean ±SD decrease in HBV 
DNA viral load was -6.0 ±0.98 log10 copies/mL. One subject 
achieved HBeAg seroconversion at week 48. This subject’s 
HBV DNA level and HIV-1 RNA viral load decreased from 
8.8 and 4.0 log10 copies/mL at baseline to 3.9 and 2.1 log10 
copies/mL, respectively, at week 48. The subject’s ALT 
level normalized to 11 IU/L from a baseline value of 55 
IU/L, and the CD4 cell count increased from 114 cells/mm
3 
at baseline to 179 cells/mm
3 at week 48. 
  Three subjects each experienced a grade 3 adverse event 
that was unrelated to study drug: decreased neutrophil counts 
(1 subject), increased lipase (1 subject), and toxoplasmosis 
(1 subject who withdrew from the study). A fourth subject, 
who experienced drug-related grade 3 leukopenia that 
remained unresolved, continued on study. Three subjects had 
abnormal ALT levels during the study. 
  The results from this prospective pilot study 
demonstrated that treatment with ABC/3TC/ZDV + TDF 
was well tolerated with sustained antiviral activity through 
48 weeks against HBV and HIV-1 in HBV/HIV-coinfected 
antiretroviral-naïve subjects. The virological efficacy of 
ABC/3TC/ZDV + TDF in HBV/HIV coinfected 
antiretroviral-naïve subjects is consistent with the results 
reported by Dore, et al. [8]. During 48 weeks of therapy with 
ABC/3TC/ZDV + TDF, a mean ±SD decrease of 6.0 ±0.98 
log10 copies/mL in HBV DNA was observed in this study 
whereas a mean decrease in HBV DNA of 4.7 log10 
copies/mL was observed by Dore, et al. in antiretroviral-
naïve subjects who received antiretroviral therapy regimens 
containing 3TC and TDF. In this study, HBeAg 
seroconversion occurred in 1 subject who had good 
suppression of HBV DNA with normalization of ALT, but 
little increase in CD4 cells over 48 weeks. 
  The ABC/3TC/ZDV + TDF regimen is a twice-daily 
regimen that requires the subject to take 1 tablet of 
ABC/3TC/ZDV twice daily and 1 tablet of TDF once daily. 
This pilot study indicated that this regimen provided durable 
suppression of HIV-1 and HBV in HBV/HIV coinfected 
antiretroviral-naïve subjects. Importantly, as a NNRTI- and 
PI-sparing regimen, the possibility of preserving future 
options for HIV-1 treatment with this regimen remains. 
Current treatment guidelines either do not recommend this 
single-class regimen of ABC/3TC/ZDV+ TDF for initiation 
of HIV therapy due to limited data
 [11] but indicate that this  
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regimen can be “considered in special circumstances”
 [12] as 
it may represent a viable option for those patients in whom 
treatment with other conventional regimens may not be 
feasible due to drug interaction or tolerability issues. 
Examples of these special circumstances include women of 
childbearing potential and patients with baseline psychiatric 
illnesses requiring treatment with other medications that 
have substantial drug interactions with NNRTIs and/or PIs. 
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